Neuroblastoma is a tumour of the sympathetic nervous system which derives from embryonic cells of the neural crest. It is the most frequent solid tumour in childhood, and is characterised by strongly contrasting survival rates between young children with an early-stage tumour and older children with a late-stage tumour (Berthold et al., 1990; Bernstein et al., 1992; Mathieu et al., 1993) . The difference is so large (95% vs 20% respectively), and the progress in the treatment of late-stage, late-age tumours so slow (Huddart et al., 1993) , that it is tempting to screen for the tumour at an early age. A simple non-invasive test exists (Tuchman et al., 1987; Mathieu et al., 1993) , and a mass screening programme was started in Japan in 1985 after several pilot studies. After more than 7 years of operation, however, there is still little evidence that screening for neuroblastoma is effective (Hanawa et al., 1990; Nishi et al., 1992) , and several researchers have expressed doubts about the appropriateness of the procedure set up in Japan, suggesting in particular that screening at 6 months is too early (Cole and Parker, 1990; Bessho et al., 1991; Parker et al., 1991) . Screening efficacy for neuroblastoma is still an open question, and before embarking on large evaluation trials it is necessary to review the epidemiological and biological evidence to assess whether the evaluation of screening at an age older than 6 months is feasible, or even if it is needed at all, given the progress recently made on understanding the biology of the disease which suggests that neuroblastoma is not a single disease entity. This article is a report of work carried out within the Study Group for the Evaluation of Neuroblastoma Screening in Europe (SENSE)' to try to answer these questions. It first reviews briefly the epidemiology of the disease and the principle of screening through detection of cathecolamine metabolites. It then examines the results of programmes which screen for the disease at 6 months or earlier: this shows that this strategy mainly detects a mild form-of the disease which would not surface clinically in the absence of screening (overdiagnosis). Finally, it compares the efficacy of screening neuroblastoma at several ages as if it were a single disease entity and discusses the value of different screening strategies in the light of some recent biological results. The main emphasis is on epidemiological and biostatistical arguments, but it is essential to bear in mind several aspects of the biology of the disease in interpreting them, and in making a final decision on whether to conduct a screening trial, and on which screening strategy to evaluate.
The epidemiology of neuroblastoma Neuroblastoma occurs at various primary sites (Mathieu et al., 1993) . Therefore, its incidence is impossible to assess from routine data published by general cancer registries which record cancer by topographical site. The recent study of childhood cancer incidence by the International Agency for Research on Cancer based on diagnostic groups defined according to histology (Parkin et al., 1988) enabled international variation in this disease to be studied (Stiller et al., 1992) . The cumulative incidence up to age 15 years varied from 50 to about 170 per million among the 30 populations in which age-specific incidence was measured. There was a slight excess risk in males and, in addition, differences between various ethnic groups within the same population were evident; although part of the variation may be explained by underdiagnosis in some populations, the latter observation suggests that some variation must have an aetiological basis. Incidence in selected countries and average incidence in Europe are shown in Table I . It is noticeable that the differ- Countr-i   0  1  2  3  4  5  6  8  9 10 -14 CR2  Europe  33  21  17   13  10  6  4  3  2  1.5  1  116  Canada  36  26  23  13  6  8  4  2  2  1.3  1  126  Japan  24  23   17   16  10  7  3   2  1  2  1.3  112  U-SA  52  29  22  6  7  5  4  3  3  1.3  1.3  139 'Per million person -years: data taken from Parkin et al. (1988) . Registr data have been pooled within countries. 'Cumulative risk before 15th anniversary per million births.
ences are greater in the first year of life. an age for which under( over) diagnosis is also the highest. The incidence has increased with time in Denmark and the UK (Carlsen. 1986 : Stiller, 1993 . and the changes are especially marked in the first 2 years of life.
The current overall 5 year survival for neuroblastoma is of the order of 50%. This figure hides a wide heterogeneity among patients: patients with early-stage disease diagnosed before 1 year of age have an extremely good prognosis (5 year survival 95%). while patients with late-stage neuroblastomas diagnosed after 18 months have a 5 year survival of the order of 20%0 both age and stage are prognostic factors, and the shape of the survival curves differs according to age at diagnosis (Table II and Figure 1 ).
The overall 5 year survival has increased with time in the three countries where it has been documented (Silverberg et al.. 1990 : Stiller et al.. 1990 : Sankila et al.. 1993 . In the UK it tripled between 1970 and 1980 from 15% to 43%. However. children diagnosed between age 2 and 9 years still had a poor survival probability in 1985 (-25%), reflecting the fact that the survival rate of late-stage patients has hardly improved (Stiller et al.. 1990 : Huddart et al.. 1993 .
Since neuroblastoma is defined by its histology, mortality data for this malignancy are not routinely available. In the UK. however, information on death is available from National Health Service Central Registers. enabling the neuroblastoma mortality trend to be studied (Stiller. 1993 ). An initial fall in mortality during the 1970s reflected the improvement in survival, but there is a suggestion of an increase more recently. which may result from a real increase in the incidence of the disease in the UK. Other mortality data based on smaller numbers of deaths have been published (Carlsen. 1986; Bernstein et al.. 1992) , and extensive data have been published for Japan (Hanawa et al., 1990 (Sawada et al., 1984 (Sawada et al., . 1986 (Carlsen. 1990 : Goodman. 1991 Carlsen et al., 1992 where -x = (x-+ xi, ,) 2 and A, is the incidence rate within the interval x-1x, + . The quantity ,xi+I-x,) is shown as function of lx, in Figure 3 .
Using this method, it was shown that screening at 12 months would anticipate substantially (more than 3 months) the diagnosis for 20.5 The corresponding power of such a design depends on the numbers of births in the screened and control populations. the anticipated reduction in mortality, the number of birth cohorts enrolled and the number of years of follow-up (see Figure 4) . The expected number of deaths contributed by subjects detected at screening was calculated from the expected prevalence and from the survival probability of cases detected by screening. The values of these latter probabilities were based on clinical experience and were made dependent on the anticipation of diagnosis by screening (Table III) . The number of expected deaths contnrbuted by those unscreened or undetected at screening was calculated from a survival curve with the shape shown in Figure 1 , and adjusted to give the age-specific 5 year survival provided by the ENSG database (see Table II ). Expected mortality in the screened and unscreened populations was thus obtained from the incidence, prevalence and survival, and the resulting figures are given in Table IV . It is seen that the reduction is around 15% for one screen whatever the age at screening. (1992a) . who based their power calculation on an unrealistic reduction of mortality of 57%.
Discussio
There is a dogma among epidemiologists which states that when a screening programme has been offered as a service to a population without prior evaluation being made, it is no longer possible to make such an evaluation in this population. However, it is useful to remember that screening for cervical cancer has been evaluated in this way (Hakama et 'Under the hypothesis of the same number of births in the control population and supposing that compliance is 100%. bNumber of birth cohorts entering the study population. Only a subset of them are informative if the analysis is done at follow-up 0: the number of informative cohorts depends on the age at screening (see Figure 4) (Berthold et al.. 1991). Secondly. study of the false negatives observed in the Japanese screening programme should help us to understand more precisely the natural history of the disease. but very few such studies have been published. An analysis of 13 false negatives suggests that the preclinical phase was shorter than 17 months on average (range 1 -54) (Nakagawara et al.. 1991) . Another six false negatives were detected between ages 23 and 47 months (Ishimoto et al., 1990) . Taking the two series together, 50% of the false negatives had a sojourn time less than 17 months, suggesting that the mean sojourn time used in our calculation is unlikely to be an underestimate.
The variance of the distribution of sojourn time is at best roughly estimated. It is. however, likely that it is less precise for late cases, who contribute very little to the prevalence at screening ( 1 % from age 5 months onwards). Although (Brodeur et al.. 1992) . Considering all the evidence together. and given that ploidy and probably N-mv-c amplification (Brodeur et al.. 1987) 
